Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics.
Also known as 'human heart-in-a-jar', Novoheart’s bioartificial human heart constructs are created using state-of-the-art stem cell and bioengineering approaches, and are utilized by major drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.
- Trades on TSX Venture Exchange under symbol NVH
- Strategic partnerships with a leading global pharmaceutical company and renowned academic institutions
- Creators of the world’s first bioengineered human heart pump or ‘mini heart'
- Technologies include suite of drug discovery tools: the MyHeartTM Platform of human bioengineered heart tissues, as well as hardware and software tools for measurements and analyses using cutting-edge machine learning approaches
- IP Portfolio includes 2 granted and 11 pending worldwide patents
- Founded in 2014 based on over 15 years of scientific research in top academic institutes, with C$50MM cumulative research funding
- Foundational science received major recognitions including American Heart Association’s Best Study of 2005, Ground-breaking Study of 2006, and Late-breaking Studies of 2002, 2003, 2005 and 2007, and the Spirit of Hong Kong Innovating for Good Award in 2015
- The “human-heart-in-a-jar” technology was selected by Google’s Solve For X as a Moonshot Project in 2015
Prof. Ronald Li is a co-founder of Novoheart, and has been serving as the CEO since 2016. He is concurrently Director of Ming-Wai Lau Centre for Reparative Medicine, HK node, Karolinska Institutet (KI), Sweden. Prof. Li has been an advocate of stem cell technology for many years, starting from his career as Assistant Professor of Cardiology, and Cellular and Molecular Medicine at the Johns Hopkins University (JHU) School of Medicine. He founded and led the Human Embryonic Stem Cell Consortium when he was recruited in 2005 to become a tenured Associate Professor at the University of California, Davis, in light of state’s USD3-billion stem cell initiative Proposition 71. Prof. Li also co-directed the Section of Cardiovascular Cell & Tissue Engineering in Icahn School of Medicine at Mount Sinai with Prof. Kevin Costa. Prof. Li has received multiple accolades and recognitions during his career, including the Spirit of Hong Kong Innovating for Good Award by the South China Morning Post (2015), the Top Young Faculty Award (2002, 2004), the Top Prize for the Young Investigator Basic Research (2001) and Top Postdoctoral Fellow Helen Taussig Award (2001) of JHU School of Medicine, Young Investigator Award 1st Prize from the Heart Rhythm Society (2002), and the Career Development Award from the Cardiac Arrhythmias Research & Education Foundation (2001). Prof. Li graduated with his B.S. with honors in Biotechnology from University of Waterloo, Ontario, on Dean’s List and his Ph.D. in Cardiology/Physiology at the University of Toronto.
Prof. Costa is one of the scientific co-founders of Novoheart, and has served as the CSO since 2017. He is Director of Cardiovascular Cell and Tissue Engineering at the Icahn School of Medicine at Mount Sinai in New York City, and was previously trained at the Johns Hopkins University and on the faculty as Associate Professor of Biomedical Engineering at Columbia University. As a "blue-blood" biomedical engineering (BME) expert (B.S. and M.S. in BME from Boston University, Ph.D. in BME from UC San Diego, and postdocs in BME from JHU and Washington University) in cell and tissue biomechanics and cardiac tissue engineering, he has developed one of the first engineered cardiac tissue systems and is an inventor of several cardiac tissue engineering technologies. Since 2009, he has been working with Prof. Ronald Li to translate such systems into human cells. Prof. Costa has received research funding from the Whitaker Foundation, the National Science Foundation (NSF) and the National Institutes of Health (NIH; NHLBI, NIBIB, and NIGMS). He was also a recipient of the prestigious Faculty Early Career Development (CAREER) Award from the NSF.
Dr. Gabriel Wong obtained both his B.A. and Ph.D degrees at the University of Cambridge, U.K., the latter under the supervision of Dr. Michael Hastings at the Medical Research Council Laboratory of Molecular Biology in Cambridge, studying mammalian cellular circadian rhythms. He underwent his first postdoctoral training at the Department of Applied Biology and Chemical Technology at the Hong Kong Polytechnic University, followed by joining the laboratory of Prof. Ronald Li and Dr. Camie Chan at the University of Hong Kong in 2013, where his primary research interest was the role of autophagy as a stress coping mechanism in the human heart, using human pluripotent stem cell-derived cardiomyocytes as an in vitro model. He acquired during this experience the training and expertise in the field of cardiac tissue engineering. He joined Novoheart in 2015, where he serves as V.P. Scientific Development managing the research team in the application of the MyHeartTM platform of cardiac tissue constructs in drug screening projects.
Our legal name is Novoheart Holdings Limited. Novoheart™ is a registered trademark. We are happy for you to quote us as “Novoheart” within editorial material.
Editorial publications are welcome to use other trademarks held by Novoheart Holdings Limtied including its corporate logo and MyHeart™ Platform name. No brand assets owned by Novoheart Holdings Limited's should be used within the creation of any other logo or in any application, product or service that is sold or provided to others.
You also agree to promptly update your use of our Brand Assets in the event we change them.
Please do not:-
- Copy, modify, imitate or use our Brand Assets in a confusing way, including suggesting sponsorship or endorsement by Novoheart or in false association with Novoheart with another brand (including your own).
- Use our Brand Assets in a disparaging manner, or show Novoheart or our products in a false or derogatory light.
- Use any logos or imagery to represent Novoheart other than what is found under our guidelines.
- Change the color, rotate or edit the structural design of our logo.
- Use the Novoheart name, the Novoheart logo or any other confusingly similar marks on any apparel, product, toy, or any other merchandise.
- Register or use any trade name, trademark logo, domain name (including without limitation, so-called “internationalized” domain names), sub-domain or URL path or any other name or sign that incorporates any of our Brand Assets (in whole or part) or that is confusingly similar to them.
Except for the limited right to use as expressly permitted under the above guidelines, no other rights of any kind are granted hereunder, by implication or otherwise. If you have any questions regarding these Guidelines, please submit your query to us.